Third Xarelto Bleeding Lawsuit Trial Set To Start Next Week In Mississippi Federal Court

   

Xarelto Bleeding Lawsuit Filings Allege Patients Suffer Brain Bleeds, Hemorrhagic Stroke, Internal Bleeding And Even Death After Taking The Blood Thinner.

Xarelto Bleeding Lawsuit xarelto-lawsuit-side-effects-lawyerA third Xarelto lawsuit trial will begin next week after the judge denied the defendants’ motion for summary judgment. The Xarelto bleeding lawsuit mirrors thousands of Xarelto complaints pending in multidistrict litigation (MDL) in the U.S. District Court, Eastern District of Louisiana. Plaintiffs and their survivors claim Xarelto caused them to suffer gastrointestinal bleeding, internal bleeding, cerebral bleeding, and other serious bleeding injuries that required hospitalization. (In Re: Xarelto (Rivaroxaban) Products Liability Litigation—MDL No. 2592)

“We have spoken with many people taking Xarelto that have described life-altering bleeding complications, and we’re hoping the jury finds Bayer HealthCare and Janssen Pharmaceuticals failed to warn of the potential risks associated with the blood thinner” says Southern Med Law’s Founder, Dr. François Blaudeau.

The attorneys at Southern Med Law represent men and women who have developed life-threatening bleeding events after taking blood thinners. The firm continues to speak with people from around the country and urges those who have experienced serious internal bleeding or other complications allegedly after taking Xarelto or other blood thinners, to contact Southern Med Law to learn more about your legal rights. You can arrange for a free, no-obligation Xarelto lawsuit evaluation by calling Southern Med Law today at 205-547-5525 or visit www.southernmedlaw.com for more information and to fill out a contact form.

The third trial involves a Mississippi woman who underwent a right total hip replacement in January 2015. After the procedure, she developed deep vein thrombosis and was prescribed Xarelto. The following month, the woman suffered gastrointestinal bleeding, according to her complaint. The plaintiff contends Bayer HealthCare and Janssen Pharmaceuticals failed to warn about the bleeding side effects associated with Xarelto. The defendants filed a motion for summary judgment maintaining they lacked the authority to change Xarelto’s drug label to warn about the bleeding risks. The defendants further contended that state claims brought by the plaintiff were pre-empted by federal law. U.S. District Judge Eldon E. Fallon denied the defendants request for partial summary judgment. The trial will held in the Southern District of Mississippi. (Xarelto Bleeding Lawsuit – Case No. 2:15-cv-03469, In Re: Xarelto (Rivaroxaban) Products Liability Litigation—MDL No. 2592)

Xarelto (rivaroxaban) is a new coagulant first approved in 2011 by the U.S. Food and Drug Administration (FDA). The blood thinner is prescribed to prevent strokes, deep vein thrombosis, pulmonary embolism, and blood clots in patients with atrial fibrillation not caused by a heart valve problem.
Xarelto is promoted as being more convenient to use than warfarin (Coumadin, Jantoven), the oldest FDA-approved blood thinner. Xarelto has similar effectiveness to warfarin, according to Bayer. However, patients who take Xarelto do not have to undergo routine blood monitoring as do patients taking warfarin. According to the FDA, warfarin uses vitamin K as an antidote for the medication’s anti-clotting effects. Xarelto does not have an approved-FDA antidote should adverse bleeding episodes occur.
[xarelto-us.com/blood-thinner/xarelto-vs-warfarin]
[fda.gov/Drugs/NewsEvents/ucm405148.htm]

Xarelto lawsuits contend Bayer HealthCare and Janssen Pharmaceuticals, which makes and markets Xarelto, did not warn doctors and their patients that Xarelto may cause irreversible and life-threatening bleeding. According to one recently filed Xarelto complaint, a woman took the anticoagulant from July 2012 to March 2015 to treat atrial fibrillation. In December 2014, the woman experienced acute gastrointestinal bleeding and anemia, the complaint said. Three months later she suffered gastrointestinal bleeding and respiratory failure. She died in March 2015. (Xarelto Bleeding Lawsuit Case No. 2:17-cv-05982, In Re: Xarelto (Rivaroxaban) Products Liability Litigation—MDL No. 2592)

About Southern Med Law And Filing A Xarelto Bleeding Lawsuit

Throughout his career, Dr. Blaudeau has worked hard to develop a strong reputation in healthcare litigation. His first-hand knowledge of medicine has made the Southern Med Law team an aggressive and effective attorney and advocate for those who were harmed due to negligent pharmaceutical companies. If you or a loved one where harmed by Xarelto, please contact Southern Med Law today to learn more about your legal rights. Call today for a free, no obligation Xarelto lawsuit review by filling out our online form, or by calling the office directly at 205-547-5525.

Southern Med Law
François M. Blaudeau, MD JD FACHE FCLM Esquire
2224 1st Avenue North
Birmingham, Alabama 35203
Phone: (205) 547-5525
Fax: (205) 547-5526
francois@southernmedlaw.com
Medical Negligence/MedicalDevice/Pharma/Qui Tam
www.southenmedlaw.com

This entry was posted in Southern Med Law | Article. Bookmark the permalink.